SCHEMBL23609012

SCHEMBL23609012

O=C(Nc1ccc(NCCn2cncn2)c(-c2ccccc2)c1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
AKT1 P31749 4/20 0.41
ACE2 Q9BYF1 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 1/20 0.40
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
KCNK3 O14649 2/20 0.39
BCAT2 O15382 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608977 0.92 PKM (0.43) PKMMAPTALDH1A1HPGDACE2
SCHEMBL23609003 0.83 SMN1; SMN2 (0.44) MAPTALDH1A1SMN1; SMN2HTTKDR
SCHEMBL23608999 0.81 CYP19A1 (0.43) MAPTALDH1A1SMN1; SMN2HTTFLT1
SCHEMBL23609230 0.78 SMN1; SMN2 (0.46) MAPTALDH1A1SMN1; SMN2HTTMEN1
SCHEMBL23609023 0.77 CSNK2A2 (0.46) MAPTALDH1A1SMN1; SMN2HTTKDR
SCHEMBL23609145 0.76 FLT1 (0.43) MAPTALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL23609806 0.76 GSK3B (0.48) PKMMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL23609050 0.76 CYP1A2 (0.45) MAPTALDH1A1FLT1KDRHDAC1
SCHEMBL23609143 0.76 SMN1; SMN2 (0.41) MAPTALDH1A1SMN1; SMN2HTTMEN1
SCHEMBL30406454 0.76 CYP1A2 (0.45) MAPTALDH1A1FLT1KDRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
EP-4081199-A2 LIPOXYGENASE INHIBITORS SRI International (US) 2022-11-02 EP disclosed
CN-115135316-A Lipoxygenase inhibitors 思研(SRI)国际顾问与咨询公司 2022-09-30 CN disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 PKM 1454/4885MAPT 2110/4885ALDH1A1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.